About
Signatur Biosciences develops molecular diagnostic kits that condense complex RNA signatures into single qPCR assays so standard qPCR machines can deliver precision diagnostic information. Their platform is aimed at decentralizing molecular diagnostics for conditions such as breast cancer prognosis and integrating with existing hospital qPCR workflows.
Explore Signatur Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.